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1 Aalborg University Hospital, Aalborg, Denmark, 2Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark
Pemphigus vulgaris is an autoimmune skin disorder with development of blisters in the
skin and mucosa, and it can be a life-threatening disease if not treated. Corticosteroids
have been a cornerstone for treating PV, but because of side effects the treatment is
combined with other conventional immune modulating drugs and rituximab. The Danish
treatment protocol for pemphigus vulgaris is similar to the other Scandinavian countries,
and therefore this study is of importance for clinicians in the Scandinavian countries
as well as other European countries. We retrospectively identified all patients with
Pemphigus vulgaris in our tertiary center over a 7-year period in order to register patient
characteristics, treatment, adverse events, comorbidities and the effect of prednisolone
dose on remission. In this study 19 patients met the inclusion criteria and remission was
seen after a mean of 19.9 weeks, and relapse was seen in 50% after the mean time of
15 weeks. Time to relapse in our study is relatively short compared to studies in which
rituximab is used as a first-line drug in treating pemphigus vulgaris.
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INTRODUCTION
Pemphigus vulgaris (PV) is an autoimmune skin disorder with development of blisters in the skin
and in mucosa. PV is caused by autoantibodies attacking desmoglein 1 (Dsg1) and 3 (Dsg3), which
are responsible for cell-cell adhesion. Binding of autoantigens to the intercellular connections leads
to disruption of cell-cell adhesion, called acantholysis (1, 2).
Clinical features of PV consist of blisters in the oral cavity and cutaneous flaccid blisters
that easily rupture, leaving the skin with painful erosions that easily become infected (3).
Immunofluorescence is used to detect immunoglobulin (IgG) or C3 deposition on the
basement membrane.
PV is a chronic disorder and can be fatal if not treated (3). Systemic treatment with high doses of
corticosteroids is regularly given. Because of the severe side effects of corticosteroids, treatment is
combined with other immune modulating drugs and/or rituximab to keep the steroid dose as low
as possible (1, 4–6).
BACKGROUND
From former studies of bullous pemphigoid (7), we know that high dose prednisolone
(>45mg/day) treatment is associated to longer admission time. However, no association between
high/low corticosteroid dose and remission rate, relapse rate and treatment length was found.
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We considered whether corticosteroid treatment regimen
was associated to remission, relapse and/or comorbidities in
patients with pemphigus vulgaris? Therefore, the aim of the
present study was to record total doses of prednisolone
given to patients with PV either solely or in combination
with other immunosuppressants. Additionally, comorbidities
acquired before, during, or after diagnosis of PV were listed and
a mortality rate was calculated (8–10).
METHODS
The medical records were retrieved for all patients admitted
with a diagnosis of PV at the Department of Dermatology and
Venereology at Aarhus University Hospital, Aarhus, Denmark,
in the timespan 2011–2018. The project was approved by the
Danish Data Protection Agency. Patients were included if they
had had a biopsy that verified a diagnosis of PV according to the
Danish pathology database, Patoweb. Patients younger than 18
years were excluded. A biopsy was considered diagnostic for PV
if direct immunofluorescence showed deposits of IgG or C3 on
the basement membrane.
Treatment was based on the department of dermatology’s
guidelines for patients with PV.
SPSS package software was used for statistical analysis.
Graphpad Prism and Excel were used for figures. The descriptive
analysis is made on the basis of continuous variables given
as means with 95% confidence intervals (CI) and standard
deviations (SDs) and categorical variables given in percentages.
Treatment outcomes were categorical and compared using p-
values computed from Fisher’s exact test. p-values <0.05 were
considered statistically significant.
RESULTS
In the period 2011–2018, 64 patients were identified, and 19 of
these fulfilled the inclusion criteria. Ten patients were excluded
because they appeared twice. A total of 15 patients did not
fulfill the diagnostic criteria for PV and were all excluded. Due
to limited access to patients’ medical records before 2011, this
research was limited to the time period 2011–2018. Nineteen
patients were excluded because they were diagnosed with PV
before 2011. Furthermore, one patient diagnosed with PV was
below 18 years of age and was therefore excluded.
The age of PV onset ranged from 21 to 101 years, with a
mean of 57.8, 95% CI (48.4–67.3), SD 21.06. Female: male ratio
was 0.82. Five patients were of other ethnic origin than Danish,
14 patients were ethnically Danish. There was no significant
difference in age at PV onset between male and female patients
(56.3± 20.7 vs. 60.0± 22.8 years, respectively; p= 0.7).
A DXA (dual-energy X-ray absorptiometry) was performed
in 9/19 patients. Four patients developed osteopenia and one
Abbreviations: PV, Pemphigus vulgaris; IF, Direct immunofluorescence; Dsg1,
Desmoglein 1; Dsg3, Desmoglein 3; PDAI, Pemphigus Disease Area Index; SD,
Standard deviation; CI, Confidence interval; Pt, Patient; DXA, Dual-energy X-ray
absorptiometry; SEM, Standard error of mean; mg/d, milligrams per day; ABSIS,
Autoimmune Bullous Skin Disorder Intensity Score.
patient was diagnosed with osteoporosis during the first 12-
month period (Figure 2). Seven patients never had a DXA scan
even though they met the national guideline criteria for being in
a special risk category for developing osteoporosis. At the time
of diagnosis of PV nine patients had no comorbidities but two
of them developed osteopenia. Two patients did not receive any
prednisolone and one patient died within 2 months of diagnosis
(Supplementary Figure 1).
One patient became diabetic and had many prednisolone side
effects, including moon face, buffalo hump, and myopathy. The
same side effects appeared in another patient, presumably caused
by very high doses of prednisolone.
Some of the patients had comorbidities before being
diagnosed with PV, see Table 1. Three patients had hypertension,
and two of these also had hypercholesterolemia. One patient
had chronic heart failure, one had aorta insufficiency, one
had migraine, and one patient had epilepsy. Two patients had
previously been treated for cancer: one for breast cancer and
the other for colorectal cancer. Two of the nineteen (2/19) PV
patients were treated with ACE inhibitors (Enalapril) at PV
diagnosis. ACE inhibitors are known to be able to elicit or
maintain PV. However, one of the two patients discontinued
Enalapril when PV had been diagnosed. Yet, the PV disease
was unaffected by the discontinuation of ACE inhibitor in
this patient.
Prednisolone was the most widely used treatment. Seventeen
of the 19 patients received prednisolone. One patient refused
to receive prednisolone because of obesity and was treated
with cyclosporine, and the other patient was well treated on
azathioprine and topical corticosteroids. The remaining 17
patients received prednisolone along with other adjuvants.
The primary treatment regimen was prednisolone and
azathioprine, some were also given rituximab later in their course
TABLE 1 | Treatment specifications and comorbidities.
Treatment Patients
Oral prednisolone 17
Oral prednisolone and rituximab 13
Oral prednisolone and azathioprine 7
Oral prednisolone and MTX 3
Oral prednisolone and dapsone 2
Oral prednisolone and plasmapheresis 2
Comorbidities
Hypertension 3
Hypercholesterolemia 2
Chronic heart failure 1
Aorta insufficiency 1
Migraine 1
Epilepsy 1
Dermatitis herpitiformis 1
Celiac disease 1
Breast cancer 1
Colorectal cancer 1
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FIGURE 1 | Mean dose prednisolone per interval with the standard error of
mean SEM.
of treatment. Rituximab was used only for recalcitrant patients,
for patients with very severe PV disease and for patients with
contraindications to other immunosuppresants, e.g., patients
with a history of malignant disease. Themean prednisolone doses
(mg/d) were at baseline 0–3 months 27.15mg/d SD 14.9 (19
patients), 3–6months 9.26mg/d SD 9.3 (18 patients), 6–9months
3.46mg/d SD 5.4 (18 patients), and 9–12 months 2.71mg/d SD
49 (18 patients). A comparison of baseline prednisolone doses
to the other time periods revealed that the dose of prednisolone
decreased significantly over time. The changes in prednisolone
dose are shown in Figure 1.
In the 19 included PV patients, none were exclusively mucosal
dominant. Four patients had cutaneous PV, and 14 patients
had mucocutaneous PV. Most of the patients (10/19) with
mucocutaneous PV had affection of skin and oral mucosa. Three
patients with mucocutaneous PV had affection of skin, oral
mucosa, and genital (vagina or penis, respectively) mucosa.
No patients had deposition of C3 only in DIF. Eight patients
had IgG only in DIF, seven of these DIFs were done on a skin
biopsy and two were done on a mucosal biopsy from gingiva
and vagina, respectively. Five patients had C3 as well as IgG
deposition in DIF on a skin biopsy, and one patient had C3 and
IgG deposition in DIF on a mucosal biopsy from gingiva. In only
one patient of the nineteen included patients DIF was done on
both a skin and a mucosal biopsy. In this patient DIF showed IgG
deposition on the skin biopsy but no specific reactions in DIF
on mucosal (gingiva) biopsy. For additional information of DIF
data, please see Supplementary Table 1.
Almost every patient started treatment with an adjuvant
within the 1st week after onset of prednisolone treatment or 1
week later. Rituximab (1,000mg) was given as an I:V: infusion
two times at an interval of 2 weeks. This treatment was initiated
after approximately 2months of treatment with prednisolone and
other adjuvants.
One patient had recalcitrant PV and was also treated with
plasmapheresis once a month. Despite this, the patient never
achieved remission.
By dividing patients into two groups, treatment outcomes
could be compared. The groups were classified as receiving more
than or <3,782mg prednisone (mean total dose) during the
first 12 months of treatment. Treatment outcome was measured
as remission or no remission during the 12 months of follow-
up time. Remission was defined as healing of blisters and no
appearance of new blisters. The p-value was >0.05 and therefore
prednisolone dose did not have any statistically significant effect
on remission.
Remission was achieved in 16 patients at a mean of 19.9 weeks.
Relapse was defined as appearance of new bullae. Remission
followed by relapse was seen in nine patients (50%). We
calculated mean time to relapse for the whole studied group (19
patients). The mean time from remission to the appearance of
new bullae (relapse) was 15 weeks.
Minor adverse events like scalp infection, candida albicans
in the oral cavity, diarrhea, urinary tract infection, and skin
infection with Staphylococci aureus were seen in 9/19 (47%)
patients during the first 12-month period.
Three patients (16%) had major adverse events. One patient
had a single incidence of pneumonia. Another had pneumonia
followed by septicemia, and a third patient had a reactivation
of herpes zoster followed by pneumonia and septicemia and
died. Thus, the mortality rate among our patients with PV
was 5.3% (1/19) during the first 12 months of follow-up.
The mortality rate was calculated to be 37 patients per 1,000
person years.
A PDAI score was found for 18 of the 19 patients. For one
patient, it was not possible because of the poor quality of the
description in the medical record. The majority of patients had
a moderate PV according to PDAI score. Four patients had a
significant PV, and only one had an extensive disease.
Results did not show a significant correlation between PDAI
status and prednisolone dose.
DISCUSSION
We found no association between prednisolone dose (mean
total dose more than or <3,782mg) and time to remission.
The patients in this study were down-regulated in prednisolone
dose if they experienced clinical improvement. This makes
remission and prednisolone dose dependent variables, and can
explain why no association between the two variables was
found. A prospective study in which patients are randomized
to either low- or a high-dose prednisolone treatment could
contribute with valuable information on prednisolone’s role in
inducing remission.
The mean time to relapse was relatively short in this study
compared to other studies of patients with PV. This might be
due to the fact that Prednisolone treatment was tapered too fast
and before the patient achievedmaximum effect of the Rituximab
treatment. It is our clinical experience that most patients do not
achieve maximum effect of the Rituximab infusion until 8–12
weeks after Rituximab infusion.
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FIGURE 2 | Seventy six years old (at diagnosis of PV) ethnically danish woman with mucocutaneous PV, celiac disease, and former dermatitis herpetiformis as well as
essential hypertension. The patient did not receive treatment with ACE inhibitor. Skin biopsy showed acantholysis. DIF on the skin biopsy showed intercellular
deposition of IgG. The patient was treated with oral prednisolon, Methotrexate and two times Rituximab. Time to remission was 20.7 weeks which is close to mean
time to remission (19.9 weeks) in the 19 included patients. The patient received a total dose of 2,495mg prednisolone, which placed her in the “low dose
prednisolone” group. This patient was later diagnosed with osteoporosis on DXA scan.
We attempted to determine the severity of PV disease by
calculating PDAI based on information from the patient record
(11). The ability to perform precise PDAI ranging was difficult. In
a few cases, the clinician had thoroughly described size, number,
and placement of the blisters. But in the vast majority, the
information lacked precise details on location and total number
of the blisters. In particular, blisters in the oral cavity were not
described as located to a particular region of the oral cavity.
This complicated the ranging of patients according to the PDAI
and may possibly have underestimated the real PDAI score. In a
prospective study, clinicians can be educated to register objective
findings and comorbidities precisely so that the clinical data can
be used in research.
The strengths of this study are the long study period and the
validation of all PV diagnoses with direct immunofluorescence.
The Danish civil registration number register in Denmark
ensures that all procedures, administered medicine, and
consultations are systematically documented. Furthermore, all
patients’ medical records were reviewed individually.
Selection bias may have had an influence on outcomes because
themost severe cases in the region are referred to the Department
of Dermatology and Venereology at Aarhus University Hospital.
Also, the lack of patients with exclusive mucosal PV in this study
group might reflect that these patients may primarily be referred
to other departments in the hospital such as the oral surgeon unit.
The limitation of this study was the small sample size, hence
the limited use of statistics. It should be taken into consideration
that this is a retrospective study; the associations are therefore
not conclusive.
Tavakolpour et al. report that relapse of disease is expected
6–10 months after infusion of rituximab (12). In this study,
we found that 50% of the patients had a relapse after a mean
of 15 weeks. This is a markedly shorter time period than
expected. Relapse was assessed on clinical features alone and
by different clinicians every time. In the future, it could be
intriguing to also observe the serologic response in the same way
as Horváth et al. did. In Horváth et al.’s study CD20+ B cells and
specific antibodies against Dsg1 and Dsg3 were measured at the
beginning of therapy and at every scheduled visit. Horváth et al.
showed that a single course of two infusions of rituximab (500mg
each) at an interval of 2 weeks had a great effect on B-cell number
and less on Dsg3 levels (13).
Knowledge of the serologic aspects of PV could clarify the
disease process and elucidate how remission is accomplished
and maintained.
In a multiprotocol for treatment of patients with pemphigus
vulgaris or pemphigus foliaceus, Grando showed that repeated
cycles with immunoglobulin (IVIg) infusion and Rituximab
treatment combined with mitochondrion protecting drugs
resulted in rapid disease control (0.2 months), short time to
remission (1.7 months), and long time to relapse (mean time to
relapse off drugs, 15.8 months). This seems to be a very efficient
and safe treatment regimen for pemphigus vulgaris. However, the
treatment is very expensive and hence will not be applicable to all
patients or health care systems. In comparison the mean time to
relapse in our study group was 15 weeks (14).
A study by Kanwar et al. investigated the clinical and
serological difference between patients receiving two doses of
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1,000mg rituximab or 500mg rituximab 14 days apart. Their
results showed a statistically significant decline in Dsg1 and Dsg3
antibodies and a greater fall in clinical scoring in the group
receiving 1,000mg rituximab (15).
The above-mentioned studies enhance the serologic effect
of rituximab on PV. Joly et al. showed a significant reduction
in prednisolone dose in patients treated with rituximab (4).
The patients in the study by Joly et al. had recalcitrant PV.
Results showed that a single cycle of rituximab decreased the
prednisolone dose required from 94 to 12mg per day. Patients
in this study were down-regulated in prednisolone dose to
approximately 3.46mg/d after only 6 months. This dose is
considered a low dose with limited side effects.
In this study, one patient had recalcitrant PV and was
treated with plasmapheresis once a month along with other
adjuvants. Despite this, the patient never achieved remission.
Kridin et al. states that immunoadsorption is superior to
plasmapheresis. Plasmapheresis unselectively and inadvertently
removes all plasma proteins in contrast to immunoadsorption,
which removes circulating IgG autoantibodies (7).
In the study by Pfütze et al. patients treated with
immunoadsorption had lower Dsg1 and Dsg3 antibody titres
and a decrease in both skin and mucosal ABSIS (Autoimmune
Bullous Skin Disorder Intensity Score). ABSIS and PDAI are the
most often used scoring system to determine PV severity (11). In
Pfütze’s study, prednisolone was also reduced within 12 months
(16). This points at immunoadsorption as a relevant treatment
option for patients with recalcitrant PV. There are, however,
some disadvantages associated with immunoadsorption because
it is expensive and not generally available.
CONCLUSION
In conclusion, patients in this study showed clinical
improvement and remission after a mean period of 19.9
weeks. Remission did not seem to correlate with prednisolone
dose. The time to relapse (15 weeks) was relatively short in the
studied PV group compared to other studies. This calls for a
revision of our treatment guidelines in favor of more liberal use
of Rituximab and IVIg treatment. The PV treatment in this study
was primarily a combination of prednisolone and azathioprine
or rituximab. Prednisolone was reduced considerably after 12
months, and consequently the risk of side effects was lowered
over time. DXA scans must be used systematically in the clinical
setting to reduce the risk of prednisolone-induced osteoporosis
in patients with PV.
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